Sysmex Corp
TSE:6869
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (3.6), the stock would be worth ¥2 905.92 (111% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | ¥1 378 |
0%
|
| 3-Year Average | 3.6 | ¥2 905.92 |
+111%
|
| 5-Year Average | 4.1 | ¥3 277.08 |
+138%
|
| Industry Average | 2 | ¥1 581.99 |
+15%
|
| Country Average | 1.1 | ¥888.09 |
-36%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
¥860.9B
|
/ |
Jan 2026
¥502.9B
|
= |
|
|
¥860.9B
|
/ |
Mar 2026
¥506.4B
|
= |
|
|
¥860.9B
|
/ |
Mar 2027
¥544.4B
|
= |
|
|
¥860.9B
|
/ |
Mar 2028
¥569.4B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Sysmex Corp
TSE:6869
|
858.7B JPY | 1.7 | 19.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 16.1 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 3.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 4.8 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 2.9 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 4.1 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.7 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 1.7 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 10.4 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 1.9 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 5.8 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 1.9 |
| Max | 12 107 466 |
Other Multiples
Sysmex Corp
Glance View
In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care. Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.